I-Bortezomib CAS 179324-69-7 Purity ≥99.0% (HPLC) API Factory High Purity
Nikeza Abaphakathi Abahlobene Ne-Bortezomib Ngokuhlanzeka Okuphezulu
(1S,2S,3R,5S)-(+)-2,3-Pinanediol CAS 18680-27-8
(1R,2R,3S,5R)-(-)-2,3-Pinanediol CAS 22422-34-0
I-Bortezomib CAS 179324-69-7
| Igama Lekhemikhali | I-Bortezomib |
| Omqondofana | I-Velcade, MG-341, PS-341 |
| Inombolo ye-CAS | 179324-69-7 |
| Inombolo yeCAT | I-RF-API65 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C19H25BN4O4 |
| Isisindo samangqamuzana | 384.24 |
| I-Melting Point | 122.0~124.0℃ |
| Ukuminyana | 1.214 |
| I-Refractive Index | 1.564 |
| Ukuncibilika | I-Soluble ku-Chloroform, i-DMSO, i-Ethanol ne-Methanol |
| Ukuzinza | I-Hygroscopic futhi Izwela Umswakama |
| Isimo Sokuthumela | Kuthunyelwe Ngaphansi Kwezinga Lokushisa Le-Ambient |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | Impushana Emhlophe noma Engamhlophe |
| Ukuhlanzeka / Indlela Yokuhlaziya | ≥99.0% (HPLC) |
| Ukulahlekelwa Ekumisweni | ≤0.50% |
| Izinsalela ekushiseni | ≤0.20% |
| Ukujikeleza kwe-Optical | -41.0° ~ -46.0° |
| Insimbi Enzima | ≤20ppm |
| I-Acidity | 4.0~7.0 |
| Isomer | ≤0.50% |
| Ukungcola Okukodwa | ≤0.50% |
| Ukungcola Okuphelele | ≤1.0% |
| Izincibilikisi Ezisele | |
| I-Methanol | ≤0.30% |
| I-Dichloromethane | ≤0.05% |
| I-Hexane | ≤0.02% |
| I-Ethyl Acetate | ≤0.50% |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-API |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, I-Cardboard Drum, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Shanghai Ruifu Chemical Co., Ltd. ingumkhiqizi ohamba phambili kanye nomphakeli we-Bortezomib (CAS: 179324-69-7) enekhwalithi ephezulu, i-API.
I-Bortezomib, ethengiswa ngaphansi kwegama lomkhiqizo i-Velcade phakathi kokunye, umuthi wokulwa nomdlavuza osetshenziselwa ukwelapha i-myeloma eminingi kanye ne-mantle cell lymphoma.I-Bortezomib ivunyelwe ukusetshenziswa kwezokwelapha e-United States ku-2003 nase-European Union ku-2004. Isohlwini lwe-World Health Organization's List of Essential Medicines.I-Bortezomib iyi-proteasome inhibitor yokuqala okufanele ivunyelwe b i-US FDA ye-myeloma eminingi, umdlavuza wegazi.I-reversible inhibitor ye-26S proteasome-izinhlayiyana zama-multiprotein ezimise okwe-barrel ezitholakala ku-nucleus ne-cytosol yawo wonke amaseli e-eukaryotic.I-Bortezomib iyi-26S proteasome inhibitor ekhethiwe futhi eqinile, okungukuthi i-boronic acid dipeptide derivative.Ucwaningo lwamaseli omdlavuza we-pancreatic womuntu lubonisa i-Bortezomib ukuvimbela i-PKR-like endoplasmic reticulum (ER) kinase futhi ithuthukise ukucindezeleka kwe-ER, okuholela ku-apoptosis.
